Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib with or without sacituzumab tirumotecan guided by peripheral ctDNA in first-line ALK-positive NSCLC
ChiCTR2600131220Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lorlatinib and sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: 1-year progression-free survival rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lorlatinibsacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600131220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131220.